Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results

Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results

RESEARCH TRIANGLE PARK, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Tranzyme
Pharma (Nasdaq:TZYM), today announced that the Company will report fourth
quarter and full-year 2012 financial results after the close of the market on
Thursday, March 28, 2013.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering,
developing and commercializing novel, first-in-class small molecule
therapeutics for the treatment of gastrointestinal (GI) disorders. All of the
Company's product candidates have been discovered using its proprietary
chemistry technology platform, MATCH™ (Macrocyclic Template Chemistry), which
enables the construct of synthetic libraries of drug-like, macrocyclic
compounds in a predictable and efficient manner. By leveraging MATCH™,
Tranzyme is committed to pursuing first-in-class medicines to address areas of
significant unmet medical need, and continues to seek collaborative drug
discovery partnerships.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com